Member Info for deepjoy

Dave. Primary bid comes from cash you must hold in your bank account and the shares are then deposited in your broker account.. so if you are an ISA investor or have no cash in the bank you cant benefit.

Yes i just found that out the plot thickens :
Franz Walt is a businessperson who has been at the helm of 6 different companies. Mr. Walt holds the position of Chief Executive Officer & Director at Quotient Ltd., Chairman-Supervisory Board of Siemens Healthcare Diagnostics Products GmbH and President for Laboratory Diagnostics LLC. Mr. Walt is also on the board of Epigenomics AG.

In the past Mr. Walt was President & Chief Executive Officer of Roche Diagnostics España SL, Chief Executive Officer at Roche Diagnostics GmbH, President of Siemens Healthineers AG and Managing Director at Roche Diagnostics Asia Pacific Pte Ltd.

Wessex.. I am summarising that there is some connection between Orph's partner (Quotient) and channel partners (unknown) that supports NHS Englands plans for widespread NHS anti body testing.. Whether Roche is a channel partner or not is just a guessing game but clearly there was some impetus to get this deal signed with Quotient and the timescales are more than co-incidence. As far as I can tell AVCT is a red herring

of course it doesnt mean that Orph and partners wont get a cut as of the pie as demand and capacity are clearly going to be mismatched for a long time yet...

No i think Avct is looking at their BB

https://news.sky.com/story/coronavirus-free-antibody-tests-to-be-available-on-nhs-after-deal-made-with-roche-government-says-11992225

reports that the Health Secretary is to announce free anti body test for all on NHS in England after reaching deal with Roche on the 100% accurate test approved by UK porten down est... FYI

In simple terms a UT is an ' Uncrossing Trade
This is used for the single uncrossing trade, detailing the total executed volume and uncrossing price as a result of a SETS auction.

In other words it is an anomoly of the peridoic auctions on the dealing systems used by MMs (SETS)

Absolute rubbish.... used in junk stock threads to overcome framing bias...

Fairview... To be accurate the point Cathal made about anti body testing was that the demand for scale meant that there was mre than enough share in both public and private sector provision to merit investment in the deal. The point i would make is that this is but one strand of the potential for explotation for Orph Group not the one trick pony many people focus on. The interview last night changed the investment case significantly, that is to say, he no longer has any previous sale valuation in mind but want to see how much value can be extracted in the same timescales.. given the aim to list one such strand in the US it shows me he has taken steps early to exploit all opportunities. GLA

I am suprised to note this morning that no one is mentioning the clever way he talked of listing the spon off in the US. Given his background in brokerage that's a good move to take a stake in a shell ..?

Down... agree managment need to get grip on that aspect or we could have a short lived sales bubble ....

Yea i take that point Gab. Thanks

Sogamia, He stated some months ago in interviews (6p price then) that he was looking to acheive a 2x3 times uplift sale and that he was not looking to get greedy in managing investors expectations. The lottery ticket reference was also there but as he stated it is not reflected in the company book valuation. I think it was on vox and also other interviews in January

Gab, All valid points. I would just say that if he is looking to sell the company and secure a return of 200 -300% on his significant investment and that of his backers before moving on he would, perhaps wish to ensure that the company valuation was a realistic one for buyers and that shareholders also make a return. The worst thing he would want to do is price a sale out of range by an overinfated valuation not back by fundamentals?

Gab, for what it is worth I think Cathal was trying to manage expections and quell, without being direct, any unwarranted and unevidenced speculation about future earnings potential etc. His original business case and timelines were looking for circa 18p per share buy out, once profitable. I think it is important to note that he never stated anything other than to do up the company, sell and move on. He has ever stated aspirations to build a huge company, although the recent comms on increasing lab capacity seem to be at odds with this, given the cost reduction strategy he was delivering on track.
The reason I sold down by 90% last week (yes i missed big gains in doing so) was because the SP had risen to overbought levels off the back of a large seller clearing and some serious ramping. The share was trading on an overbought RSI for nine days after all and was always going to come back.
In my years of investing I have never come across a CEO/Chair so in tune with retail investors and I think it is fair to defend him because the sentiment on this share overtook his timescales for delivery i think. Just my opinion Cheers DJ

Brooko ...for the record it is I that is sparticus, not Moniman... GLA

stop clogging the board... just post alink for gawd sake ..

wait till the block sells get reported later.... they will mix them in or report after hours but this is far from being a straight book here. Sadly, i might add.

back in from the garden for a brew... and to answer your question Moni this isnt traders per se' this MMs doing the grand olds duke of york approach to increase volumes for clients to sell into.. It is simple and is why i what do a bloody thing with this now not least buy the rapid rises...